Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 6/20 | 0.46 |
| ▸ | HRH1 | P35367 | 6/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336118 | 1.00 | HRH2 (0.46) | HRH2HRH1P2RY12MEN1POLB | |
| SCHEMBL523557 | 0.81 | HRH2 (0.59) | HRH2HRH1P2RY12KMT2A | |
| SCHEMBL523558 | 0.81 | HRH2 (0.59) | HRH2HRH1P2RY12KMT2A | |
| SCHEMBL524045 | 0.81 | HRH2 (0.50) | HRH2HRH1P2RY12POLB | |
| SCHEMBL524046 | 0.81 | HRH2 (0.50) | HRH2HRH1P2RY12POLB | |
| SCHEMBL523726 | 0.80 | CTSK (0.50) | HRH2HRH1P2RY12POLB | |
| SCHEMBL523727 | 0.80 | CTSK (0.50) | HRH2HRH1P2RY12POLB | |
| SCHEMBL316794 | 0.80 | HRH2 (0.57) | HRH2HRH1P2RY12POLB | |
| SCHEMBL523554 | 0.80 | HRH2 (0.49) | HRH2HRH1P2RY12POLB | |
| SCHEMBL316793 | 0.80 | HRH2 (0.57) | HRH2HRH1P2RY12POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | HRH2 48/4885HRH1 92/4885P2RY12 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.